

Stay Current with FDA-Approved Immunotherapy Treatments

Attend an Upcoming SITC Advances in Cancer Immunotherapy™ Program in Seattle



All healthcare professionals in the clinical setting, students and patient advocates attend for FREE!

The Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) programs are CE and MOC accredited programs presented by local authorities in tumor immunology and cancer immunotherapy and are **free for healthcare professionals in the clinical setting, students, and patient advocates.**

ACI PROGRAM TAKEAWAYS

By attending this program, attendees will learn how to:

- Treat patients with lung cancer, melanoma, head and neck cancers, hematologic malignancies and genitourinary cancers with FDA-approved immunotherapies
- Interpret the most recent clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
- Identify and manage immune-related adverse events
- Employ strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice
- Apply foundational knowledge for optimized clinical implementation of SITC's Cancer Immunotherapy Guidelines

Connect with regional immunotherapy experts during these interactive in-person programs, in subsequent quarterly webinars and through a dedicated SITC CONNECT online community.

Register at sitcancer.org/aciseattle

The 2018–2019 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine and the Association of Community Cancer Centers.



The 2018–2019 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. (as of Aug. 21, 2018).

Saturday, Nov. 3, 2018

8:00 a.m.–12:30 p.m. (PDT)

Renaissance Seattle Hotel
515 Madison Street
Seattle, Wash.

PROGRAM ORGANIZERS

Andrew Coveler, MD
Fred Hutchinson Cancer Research Center

Nora Disis, MD, FACP
University of Washington

Doreen M. Higgins, RN, BSN, OCN
University of Washington

WHO SHOULD ATTEND?

- Clinical Oncologists
- Radiation Oncologist
- Primary Care Physicians
- Registered Nurses
- Advanced Practice Providers
- Pharmacists
- Emergency Physicians
- Allied Health Professionals
- Administrators and all members of the cancer care team
- Students
- Patient Advocates

